Stock 6855 ASCENTAGE PHARMA GROUP INTERNATIONAL
Add to a list
To use this feature you must be a member
Log inSign up

Company Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:06 2024-04-30 EDT 		5-day change 1st Jan Change
17.88 HKD +1.71% Intraday chart for Ascentage Pharma Group International +7.84% -34.51%
04-25 Ascentage Pharma to Present Four Studies at US Oncology Meet MT
04-09 Ascentage Pharma Chairman Boosts Stake in Firm MT

Business Summary

Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.

Number of employees: 583

Sales per Business

HKD in Million2022Weight2023Weight Delta
Pharmaceutical Products
87.2 %
203 83.4 % 214 87.2 % +5.13%
License
11.7 %
28 11.6 % 29 11.7 % +1.62%
Service
1.1 %
12 5.0 % 3 1.1 % -78.12%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
100.0 %
244 100.0 % 245 100.0 % +0.59%

Managers

Managers TitleAgeSince
Da Jan Yang CEO
 Chief Executive Officer 61 09-04-30
Ming Guo FOU
 Founder 67 09-04-30
Yi Qing Chen DFI
 Director of Finance/CFO 40 21-11-28
Yifan Zhai CTO
 Chief Tech/Sci/R&D Officer 62 13-06-30
Gang Zhu PRN
 Corporate Officer/Principal - 20-12-03
Raymond Jeffrey Kmetz PRN
 Corporate Officer/Principal - 19-01-31
Cheung Ki Wong SEC
 Corporate Secretary 41 18-07-29
Thomas Knapp LAW
 General Counsel 71 18-08-31

Members of the board

Members of the board TitleAgeSince
David Sidransky BRD
 Director/Board Member 64 21-03-30
Shao Meng Wang BRD
 Director/Board Member 60 17-11-16
Zheng Yin BRD
 Director/Board Member 52 19-06-12
Chang Qing Ye BRD
 Director/Board Member 53 19-05-31
Da Jan Yang CEO
 Chief Executive Officer 61 09-04-30
Wei Ren BRD
 Director/Board Member 43 19-06-12
Simon Dazhong Lu BRD
 Director/Board Member 55 18-07-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 290,212,060 212,890,469 ( 73.36 %) 0 73.36 %

Shareholders

NameEquities%Valuation
Yifan Zhai
22.25 %
64,585,929 22.25 % 147 M $
Zhuhai Hengqin Yuanming Asset Management Co. Ltd.
4.413 %
12,805,662 4.413 % 29 M $
Da Cheng Fund Management Co., Ltd.
1.581 %
4,587,708 1.581 % 10 M $
Bosera Asset Management Co., Ltd.
0.4964 %
1,440,500 0.4964 % 3 M $
Caitong Fund Management Co., Ltd.
0.1430 %
415,000 0.1430 % 941 730 $
Fullgoal Fund Management Co., Ltd.
0.0388 %
112,500 0.0388 % 255 288 $
Truvalue Asset Management Co. Ltd.
0.0296 %
86,000 0.0296 % 195 154 $
Xinyuan Asset Management Co., Ltd.
0.0296 %
85,800 0.0296 % 194 700 $
Yingda Asset Management Co., Ltd.
0.0258 %
74,800 0.0258 % 169 738 $
Zhonghai Fund Management Co., Ltd.
0.0219 %
63,500 0.0219 % 144 096 $

Company contact information

Ascentage Pharma Group International Co., Ltd.

Suzhou Industrial Park 68 Xinqing Road

215000, Suzhou

+86 512 8555 7777

http://www.ascentage.com
address Ascentage Pharma Group International(6855)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Sales per region

Ratings for Ascentage Pharma Group International

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.55 CNY
Average target price
27.24 CNY
Spread / Average Target
+64.62%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ASCENTAGE PHARMA GROUP INTERNATIONAL Stock Ascentage Pharma Group International
-34.51% 639M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.46% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 96.29B
ARGENX SE Stock argenx SE
+2.13% 22.18B
BIONTECH SE Stock BioNTech SE
-15.84% 21.2B
GENMAB A/S Stock Genmab A/S
-9.21% 18.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.38B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.65% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.39% 13.97B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+31.35% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6855 Stock
  4. Company Ascentage Pharma Group International